Lv4
440 积分 2025-01-23 加入
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
14小时前
待确认
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
8天前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Finerenone in Persons with Chronic Kidney Disease without Diabetes
14天前
已完结
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
19天前
已完结
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial
20天前
已完结
Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy
22天前
已完结
Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
23天前
已完结
Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
1个月前
已完结
Differential Cell–Specific, Regulatory Roles of Fcγ Receptor IIB through IgG in IgA Nephropathy
2个月前
已完结
皖公网安备34019202002308
